AKT1 and neoplasm: Furthermore, tumours with MSR1 mutations increased sensitivity to treatment with the AKT inhibitor GSK690693, according to the Genomics of Drug Sensitivity in Cancer (GDSC) project using the Pan-cancer database (193).